Yeji
NDA/BLA filedconf 0.70

NDA/BLA filed

$RARE · Ultragenyx Pharmaceutical Inc.
Event date
Date TBD
Sponsor runway
3 mo
$175.0M liquid

Evidence

“On December 30, 2025, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that that it has completed the rolling submission of its Biologics License Application ("BLA") to the U.S. Food and Drug Administration (the "FDA") seeking approval for DTX401 AAV gene therapy (pariglasgene brecaparvovec) as a treatment for Glycogen Storage Disease Type Ia ("GSDIa").”
Source: 8-K filed 2025-12-30View on EDGAR ↗0001193125-25-337099

Comparable historical nda/bla fileds· last 5 years · same event type

TickerDrugDateOutcome
$AXSM—2025-12-31unknown
$RCKTkresladi2025-10-14unknown
$ALDXreproxalap2025-07-17unknown
$ETONet-6002025-07-08unknown
$BCRXorladeyo (berotralstat)2025-05-14unknown
$CORTrelacorilant2025-03-03unknown
$ALDXreproxalap2024-11-01unknown
$AXSMaxs-072024-09-04unknown
$RCKTkresladi2023-10-02unknown
$GERNimetelstat2023-08-21unknown

Recent insider activity· ±90 days

15 insiders · 0 buys · 5 sells
Sell10b5-1
2026-05-18
SULIMAN SHEHNAAZ
Director
5,740 @ $25.12$144K
Grant
2026-05-14
Ray Amrit
Director
7,751 @ ——
Grant
2026-05-14
Dunsire Deborah
Director
7,751 @ ——
Grant10b5-1
2026-05-14
SULIMAN SHEHNAAZ
Director
7,751 @ ——
Grant10b5-1
2026-05-14
SULIMAN SHEHNAAZ
Director
14,058 @ ——
Grant
2026-05-14
WELCH DANIEL G
Director
7,751 @ ——
Grant
2026-05-14
WELCH DANIEL G
Director
14,058 @ ——
Grant
2026-05-14
Sanders Corazon (Corsee) D.
Director
7,751 @ ——
Grant
2026-05-14
Dunsire Deborah
Director
14,058 @ ——
Grant
2026-05-14
Ray Amrit
Director
14,058 @ ——
Grant
2026-05-14
Sanders Corazon (Corsee) D.
Director
14,058 @ ——
Grant
2026-05-14
Fust Matthew K
Director
14,058 @ ——
Grant
2026-05-14
NARACHI MICHAEL
Director
14,058 @ ——
Grant
2026-05-14
NARACHI MICHAEL
Director
7,751 @ ——
Grant
2026-05-14
Fust Matthew K
Director
7,751 @ ——
Sell
2026-05-05
Crombez Eric
EVP and Chief Medical Officer
344 @ $24.96$9K
Sell10b5-1
2026-05-01
Horn Howard
Chief Financial Officer
4,683 @ $24.90$117K
Grant
2026-04-22
Huizenga Theodore Alan
SVP, Chief Accounting Officer
7,348 @ ——
Grant
2026-04-22
Huizenga Theodore Alan
SVP, Chief Accounting Officer
20,241 @ ——
Grant
2026-04-16
Crombez Eric
EVP and Chief Medical Officer
59,952 @ ——
Grant
2026-04-16
Harris Erik
EVP & Chief Commercial Officer
28,895 @ ——
Grant
2026-04-16
Harris Erik
EVP & Chief Commercial Officer
49,960 @ ——
Grant
2026-04-16
KAKKIS EMIL D
President & CEO
76,745 @ ——
Grant
2026-04-16
KAKKIS EMIL D
President & CEO
132,693 @ ——
Grant
2026-04-16
Huang Dennis Karl
See Remarks
23,116 @ ——
Grant
2026-04-16
Huang Dennis Karl
See Remarks
79,936 @ ——
Grant
2026-04-16
Pinion John Richard
See Remarks
23,116 @ ——
Grant
2026-04-16
Pinion John Richard
See Remarks
79,936 @ ——
Grant
2026-04-16
Horn Howard
Chief Financial Officer
34,674 @ ——
Grant
2026-04-16
Horn Howard
Chief Financial Officer
59,952 @ ——
Grant
2026-04-16
Parschauer Karah Herdman
EVP and Chief Legal Officer
28,895 @ ——
Grant
2026-04-16
Parschauer Karah Herdman
EVP and Chief Legal Officer
49,960 @ ——
Grant
2026-04-16
Crombez Eric
EVP and Chief Medical Officer
34,674 @ ——
Sell10b5-1
2026-04-01
Horn Howard
Chief Financial Officer
4,683 @ $20.97$98K
Sell
2026-03-10
Parschauer Karah Herdman
EVP and Chief Legal Officer
3,508 @ $22.67$80K
← All catalysts for $RARE